Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aberrant signal transduction pathways in myeloproliferative neoplasms.

Leukemia - 1 Oct 2008

Kota J, Caceres N, Constantinescu S N

Abstract excerpt

The BCR-ABL-negative myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF), entered the spotlight in 2005 when the unique somatic acquired JAK2 V617F mutation was described in >95% of PV and in 50% of ET and PMF patients. For t...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Polycythemia Vera
Share to Primary Myelofibrosis
Share to Receptors, Erythropoietin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Receptors, Thrombopoietin

Share to STAT Transcription Factors

Share to Suppressor of Cytokine Signaling 3 Protein

Share to Suppressor of Cytokine Signaling Proteins

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 18769448
DOI: 10.1038/leu.2008.236

Genes

JAK2
BCR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-18769448-2026-09-04.1. Manifest publication-graph-cohort-2026-09-04.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aberrant signal transduction pathways in myeloproliferative neoplasms.PMID 18769448Read ↗

A Broad Overview of Signaling in Ph-Negative Classic Myeloproliferative NeoplasmsSemantic proximity Read ↗

Oncogenic mechanisms in myeloproliferative disorders.Semantic proximity Read ↗

Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.Semantic proximity Read ↗

Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative DisordersSemantic proximity Read ↗

Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.Semantic proximity Read ↗

The JAK2 mutation.Semantic proximity Read ↗

JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.Semantic proximity Read ↗

Biology and therapeutic targeting of molecular mechanisms in MPNs.Semantic proximity Read ↗

Myeloproliferative disordersSemantic proximity Read ↗

Genetic basis of MPN: Beyond JAK2-V617F.Semantic proximity Read ↗

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F EraSemantic proximity Read ↗

JAK2 Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.